Compare Charles River Laboratories Intl. Inc (CRL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Crispr Therapeutics AG — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Crispr Therapeutics AG trades at $53.39 (market cap $4.88B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.9× Crispr Therapeutics AG's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Crispr Therapeutics AG for 77 Days on average.
| CRL | CRSP | |
|---|---|---|
Market Cap | $14.23B | $4.88B |
Volume | 1,176,885 | 2,861,747 |
Sector | Health | Health |
52-Week High | $310.77 | $73.97 |
52-Week Low | $149.93 | $44.34 |
Typical Hold Time | 33 Days | 77 Days |
Enterprise Value | $17.06B | $3.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
